



LCHAD Retinopathy Research Update

For the Scully-Peterson Family Fund for LCHAD Retinopathy Research

Thanks to our generous donors, we are moving forward with our goal to develop a retinal gene therapy for the treatment of LCHAD retinopathy in patients. One of our first goals was to add a post-doctoral fellow to our research team, and we are pleased to announce the recent acquisition of Dr. Tiffany DeVine.

Dr. DeVine completed her doctorate in the Cancer Biology program at OHSU. Her dissertation research used a cell culture model of cancer, and explored several genetic alterations to gene expression and cell function. The skills she developed during her doctoral program will be essential as we move forward developing our LCHAD-deficient retinal model using skin cells from patients with LCHAD deficiency.

Clockwise from top: Garen Gaston, M.S., Tiffany DeVine, Ph.D., Melanie Gillingham, Ph.D., Cary Harding, M.D.

Dr. DeVine completed her Bachelors degree in biology at the University of Albany in Albany, New York before moving to Portland for graduate school. She will be working with senior research assistant Garen Gaston to complete the reprogramming of LCHAD-deficient stem cells to retinal pigment epithelium, or RPE cells, to characterize those cells, and to create and test viral gene therapy treatments. Our progress on this project will be greatly enhanced by having a full team of expert scientists, and we are excited to welcome Dr. DeVine to our group.

